Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Healthy
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
- Trial name
- NCT00581243
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Aging
Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia
The purpose of this study is to determine the respective roles of aging and schizophrenia in the regulation of metamemory using a sentence construction strategy.
- Trial name
- Metamemory 2 (NCT02932059)
- Testing
- Metamemory
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Schizophrenia
Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication
The purpose of this study is to evaluate clinical meaning of EEG changes in antipsychotic-treated patients with schizophrenia.
- Trial name
- NCT00698295
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia, Dementia
Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
Use Huperzine-A, a herbal supplement normally used for treatment of Alzheimer's disease, to potentially improve cognitive dysfunction (memory problems) and functional capacity (ability to perform common daily tasks such as…
- Trial name
- NCT01012830
- Testing
- Huperzine A
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Nebraska Western Iowa Health Care System
Schizophrenia, Schizoaffective Disorder
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT02566057
- Testing
- PGx testing guided treatment (PGT)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
Schizophrenia, Aging
Functional Rehabilitation for Older Patients With Schizophrenia
Aging and psychosis are major priority areas for VA. This project is a continuation of a Merit Review Program, in which we developed, manualized and conducted randomized controlled trials of a novel psychosocial rehabilitation…
- Trial name
- FROPS (NCT00712075)
- Testing
- CBSST+PDA, Cognitive Behavioral Social Skills Training, PDA-only
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- US Department of Veterans Affairs
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
52-week Open Label Safety-Tolerability Study
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
- Trial name
- NOVA3 (NCT07369154)
- Testing
- LB-102
- Where
- 23 sites in United States
- Volunteers
- 900 people
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia, Schizoaffective Disorder
Video as a Tool to Improve Insight in Schizophrenia
The deficit of awareness of pathology (or insight) is a common symptom in patients with schizophrenia and has a negative impact on the prognosis of the disease.
- Trial name
- VideoInsight (NCT02664129)
- Testing
- Video self-observation, Non Self video observation
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Chronic Mental Illness, Schizophrenia
Exploring the Health Effects of Group Game-based Activities on Individuals With Chronic Mental Illness
This study aims to explore the health effects of group games for patients with chronic mental illness. The goal of this clinical intervention study is to compare the efficacy of group games in two ways (experimental group/ group…
- Conditions
- Chronic Mental Illness, Schizophrenia, Psychiatry
- Trial name
- NCT06440200
- Testing
- group gamed-based activity
- Where
- Taiwan
- Volunteers
- 109 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Schizophreniform Disorder
Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia
Pregnenolone (PREG) is a neurosteroid, which displays multiple effects on the central nervous system, and may be beneficial in the treatment of patients with schizophrenia.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorders
- Trial name
- PREG-2008 (NCT00847600)
- Testing
- Pregnenolone
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Schizophrenia, Physical Activity
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
In this study, an APA program by web (e-APA) will be offered to two groups of participants (21 patients and 21 healthy volunteers (HV)) in remote video (use of the SAPATIC (Santé Activités Physiques Adaptées utilisant les…
- Conditions
- Schizophrenia, Physical Activity, Schizo Affective Disorder
- Trial name
- PEPSYV@SI (NCT03261817)
- Testing
- Physical activity (APA), Health Education program (HE)
- Where
- France
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Schizophrenia
An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as compared with placebo in the treatment of participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01299389
- Testing
- Paliperidone palmitate
- Where
- 56 sites in Japan, South Korea and 1 more
- Volunteers
- 323 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
- Trial name
- NCT00083668
- Testing
- Paliperidone ER
- Volunteers
- 619 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from…
- Trial name
- NCT00428350
- Testing
- Quetiapine Fumarate (Seroquel)
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Schizophrenia
A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia
A double-blind, randomized, placebo-controlled trial of celecoxib as an add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200 treatment-naive first-episode patients with schizophrenia.
- Trial name
- NCT00686140
- Testing
- celecoxib
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia, Schizophreniform Disorder
Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT02137993
- Testing
- A-prexa, Zyprexa
- Volunteers
- 64 people
- Sponsor
- HK inno.N Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.